• search
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Development and Manufacturing

Development and Manufacturing

High-quality and flexible scale development and manufacturing services for Biotherapeutics and Cell and Gene Therapy (CGT).

Aurigene Pharmaceutical Services is rapidly positioning itself to provide end-to-end integrated development and manufacturing offerings in traditional and advanced drug modalities. Our mAb and protein therapeutics development is supported by in-house physiochemical and bio analytical development. We have a state-of-the-art cGMP viral vector manufacturing facility being commissioned.

Our manufacturing services cater to both GMP and non-GMP manufacturing for preclinical development as well as GMP operations to support clinical or commercial needs for any recombinant protein expressed in suspension mammalian culture or E.coli.

We have technological flexibility in both stainless steel and single-use bioreactor systems, as well as ability to undertake alternating tangential flow for commercial scale manufacturing.

We undertake an integrated approach to our quality management system that enables greater flexibility and leverage pan – organization experience in managing regulatory audits.

Speak to our experts

mAb and Protein Therapeutics

We provide comprehensive capabilities for mAb and protein therapeutics development. It is supported by in-house physiochemical and bio analytical development. Our strength is built on a deep understanding of cell culture, protein chemistry and an integrated analytics platform enabling a robust, scalable, controlled process.

Our approach to mAb and protein therapeutics development is based on a balance of ‘Productivity, Quality and Stability’. This approach is enabled by a collaboration between the molecular biology and the analytical teams to maximize the long-term sustainability of clones and proteins.


Aurigene Pharmaceutical Services provide Plasmid DNA production service. We provide both Research grade and GMP ready plasmids.

Research grade plasmids are used for in vitro applications in cloning, mutagenesis, microbial transformation and protein production. GMP ready plasmids are used in IVT mRNA, protein and mAb production, stable cell line generation, bacmid generation, viral packaging, vaccine, gene therapy studies and animal immunization.

Production scale:

  • Small-scale (0.1 to 1 mg)
  • Medium-scale (up to 10 mg)
  • Large-scale (100 mg to 1 g)


Analytical services are used to identify, isolate or quantify molecules and to characterize their physical properties. Aurigene provides physiochemical and biological characterization services.

Backed by our strong protein chemistry background, we enable ‘Finger-Print’ protein structure and functional characterization for proteins from naked proteins to hyper-glycosylated or derivatized proteins.

Our biological characterization capability enables a sound understanding of the biological mechanism of action of the product. We can support a wide variety of biological assays including, cell-proliferation/killing, binding affinity, cell signaling and viability or endpoint assays using both transformed cell lines and primary cells.

Fill Finish

With over 10,000 Sq.m of Fill Finish footprint, we can support filling of a wide range of presentations – Vials (Liquid and Lyophilized), Pre-filled Syringes and Autoinjectors.

Automation equipped; our filling capability addresses – High Accuracy – High Concentration – High Viscosity – Low Volume – protein filling. End-to-end single use capability enables for faster change over and assurance of cleaning validation.

Our integrated approach to quality management systems enables greater flexibility and leverage pan -organization experience in managing regulatory audits.

Why Aurigene Pharmaceutical Services?

High quality and flexible scale production

One Stop Solution

Development supported by digital infrastructure

Integrated approach to safety and quality management systems

Integrated QC testing and release

Diverse platform of instruments and technologies

In-house capability across the value chain with a trained scientific staff

Virtual Tour


Contact Us

CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug


Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.